New Phase 2 Trial to Test Survodutide for Chronic Kidney Disease

Chronic Kidney Disease (CKD) is a progressive condition characterized by a gradual loss of kidney function, often leading to kidney failure. A key indicator of CKD progression and severity is albuminuria, the presence of albumin (a protein) in the urine, which signifies kidney damage. Current treatments can slow progression but often don't fully halt it, leaving a significant unmet medical need. This study aims to investigate if survodutide can effectively reduce albuminuria in CKD patients, regardless of their diabetes status.

As this trial is currently NOT_YET_RECRUITING, there are no findings to report yet. However, the primary objective is to determine if Survodutide leads to early, sustained, and clinically meaningful reductions in albuminuria. Researchers hypothesize that weekly administration of Survodutide will significantly improve kidney function, potentially demonstrating a substantial reduction in albuminuria levels, with a target p<0.05 for the primary endpoint. The study aims to show that these benefits are consistent across patients, irrespective of their diabetes status, expecting a clinically relevant percentage reduction in albuminuria compared to placebo. The central hypothesis is that Survodutide will achieve early, sustained, and clinically meaningful reductions in albuminuria in patients with CKD, regardless of diabetes status, potentially offering a new therapeutic avenue.